// App-Quantinova.ai

723 : Risk of Major Adverse Cardiovascular and Venous Thromboembolism Events in Patients with Rheumatoid Arthritis Exposed to JAK Inhibitors versus Adalimumab: A Nationwide Cohort Study

Researchers

Presenter

  • Lea Hoisnard

Principal Investigators

  • Laura Pina Vegas

  • Rosemary Dray-Spira

  • Alain Weill

  • Mahmoud Zureik

  • Emilie sbidian

Medical Centers

  • Fédération Hospitalo-Universitaire TRUE InnovaTive theRapy for immUne disordErs, Assistance Publique-Hôpitaux de Paris (AP-HP), Henri Mondor Hospital, Créteil, France

  • Service de Rhumatologie, Hopital Henri-Mondor, Creteil, France

  • EPI-PHARE Scientific Interest Group in Epidemiology of Health Products, French National Agency for Medicines and Health Products Safety, French National Health Insurance, Saint-Denis, France

  • Service de Rhumatologie, Hopital Henri-Mondor, Creteil, France

Locations

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Blood/haematological Diseases

  • Cardiovascular (CVS)

  • Pulmonary/Respiratory Diseases

Disease

  • Venous thrombosis

  • Rheumatoid arthritis

  • Inflammatory Arthritis

Biomarkers

  • Janus kinase

Drug/Treatment

  • Adalimumab

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved